処方箋から転写へ:薬物標的としてのゲノム配列

Cong Guo¹, Anthony M D'Ippolito¹, Timothy E Reddy²

¹Center for Genomic and Computational Biology, Duke University Medical School, Durham, NC 27708, USA; University Program in Genetics and Genomics, Duke University Medical School, Durham, NC 27708, USA.

Cell

|July 4, 2015

まとめ

遺伝的差異は薬の有効性に影響する. ソチオ et al. ソチオなど. ノン・コーディング・バリエーションが,抗糖尿病薬であるロシグリタゾンの活動を変化させ,パーソナライズド医療への道を開く方法を発見した.

科学分野:

ファルマコゲノミクスは,
分子生物学は分子生物学である.
遺伝学遺伝学とは

背景:

パーソナライズド医学は,個々の遺伝的変異に基づいて治療法を調整することを目的としています.
薬物反応の変動性は,治療結果に大きく影響を与えます.
薬物の代謝に対する遺伝的影響を理解することは,治療の有効性を最適化するために不可欠です.

研究の目的:

ノンコーディング遺伝子変異がロシグリタゾンの活性に影響するメカニズムを調査する.
抗糖尿病薬に対する反応に影響を与える新しい遺伝的要因を特定する.

主な方法:

患者集団における非コーディング変異の分析.
遺伝子発現とタンパク質活性に対する変異の影響を評価するための機能的測定法.
ロシグリタゾンを用いた薬理学的研究.

主要な成果:

ローシグリタゾンの活性を調節する特定の非コーディング変異体の特定.
これらの変種が効果を発揮する分子経路の解明.
特定された変異体の存在において,薬剤反応の変化の実証.

結論:

ノンコーディング・バリエーションは,ロシグリタゾンに対する個々の反応を決定する上で重要な役割を果たします.
これらの発見は,抗糖尿病薬の有効性の遺伝的根拠についての新しい洞察を提供します.
この研究は,個別化された抗糖尿病治療戦略を導くために遺伝情報が持つ可能性を強調しています.

さらに関連する動画

08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

7.2K

関連する概念動画

01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

01:26

Targets for Drug Action: Overview

11.5K

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

11.5K

01:26

Drug Discovery: Overview

13.4K

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

13.4K

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

01:05

Maxam-Gilbert Sequencing

13.7K

In the same year as the discovery of the Sanger sequencing method, another group of scientists, Allan Maxam and Walter Gilbert, demonstrated their chemical-cleavage method for DNA sequencing. The Maxam-Gilbert method relies on using different chemicals that can cleave the DNA sequence at specific sites, the separation of resulting DNA fragments of variable size using electrophoresis, and deciphering the DNA sequence from the resulting gel bands.
Challenges of the Maxam-Gilbert Method
The...

13.7K

03:00

Next-generation Sequencing

101.7K

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....